FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136702976> ?p ?o ?g. }

• W2136702976 abstract "Castration resistant prostate cancer (CRPC) is a leading cause of cancer-related deaths in men. The primary cause of mortality and morbidity in patients is bone metastases and remodeling resulting in osteoblastic and osteolytic lesions. Recently, cabozantinib, a multi-kinase inhibitor (VEGFR2 and c-MET inhibitor), was shown to have efficacy on bone lesions in patients. In this study we tested multi-kinase inhibitors: axitinib (VEGFR inhibitor) and crizotinib (c-MET inhibitor) in a combination trial in mice models.VCaP-Luc cells were grown as subcutaneous implants in intact and castrated NOD-SCID-gamma (NSG) mice to confirm the androgen dependency. For bone metastasis model two cohorts of NSG mice (castrated and intact) received orthotopic injection of VCaP-Luc cells into the bone marrow cavity of left tibia. Mice were monitored weekly for tumor growth using bioluminescence imaging. Animals were randomized into 4 groups based on the tumor bioluminescence signal: vehicle, crizotinib alone, axitinib alone, crizotinib and axitinib in combination. Animals were imaged weekly by in vivo 2-D X-ray imaging to monitor bone remodeling. At the end of the study animals were euthanized and both tibias were extracted for ex vivo high-resolution 3-D micro-computed tomography (μCT) imaging.Subcutaneous model showed that androgen stimulation may be helpful but not essential for the growth of VCaP-Luc cells. VCaP-Luc cells grown intra-tibially in intact animals caused extensive remodeling of bone with mixed osteoblastic (bone formation) and osteolytic (bone matrix dissolution) lesions. The osteoblastic lesions were predominant and at times extended beyond the tibial shaft into the surrounding tissue. In contrast, only osteolytic lesions were prominent throughout the study in castrated animals. Treatment with crizotinib alone reduced the osteolytic lesions in castrated animals. Axitinib alone reduced the osteoblastic lesions in the intact animals. Combination therapy with axitinib and crizotinib remarkably inhibited the tibial remodeling by VCaP-Luc cells which resulted in a significant reduction of both osteoblastic and osteolytic lesions.Our data show that combined inhibition of c-MET and VEGFR can be beneficial for treatment of metastatic bone disease in CRPC and that the drugs act on two different stages of the disease." @default.
• W2136702976 created "2016-06-24" @default.
• W2136702976 creator A5002433717 @default.
• W2136702976 creator A5011934704 @default.
• W2136702976 creator A5027500644 @default.
• W2136702976 creator A5048718607 @default.
• W2136702976 creator A5062856863 @default.
• W2136702976 creator A5070293723 @default.
• W2136702976 creator A5074923974 @default.
• W2136702976 creator A5074942308 @default.
• W2136702976 creator A5086027443 @default.
• W2136702976 date "2014-10-02" @default.
• W2136702976 modified "2023-10-16" @default.
• W2136702976 title "Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer" @default.
• W2136702976 cites W1972190525 @default.
• W2136702976 cites W1981266896 @default.
• W2136702976 cites W1982989784 @default.
• W2136702976 cites W1991355732 @default.
• W2136702976 cites W2000792691 @default.
• W2136702976 cites W2002626138 @default.
• W2136702976 cites W2019008302 @default.
• W2136702976 cites W2022036429 @default.
• W2136702976 cites W2022301248 @default.
• W2136702976 cites W2027503034 @default.
• W2136702976 cites W2028387248 @default.
• W2136702976 cites W2038056960 @default.
• W2136702976 cites W2044688476 @default.
• W2136702976 cites W2053662837 @default.
• W2136702976 cites W2055489437 @default.
• W2136702976 cites W2057734107 @default.
• W2136702976 cites W2065916018 @default.
• W2136702976 cites W2081365151 @default.
• W2136702976 cites W2086629391 @default.
• W2136702976 cites W2094492848 @default.
• W2136702976 cites W2094554815 @default.
• W2136702976 cites W2100945326 @default.
• W2136702976 cites W2104923745 @default.
• W2136702976 cites W2106932520 @default.
• W2136702976 cites W2111254482 @default.
• W2136702976 cites W2121076737 @default.
• W2136702976 cites W2128557201 @default.
• W2136702976 cites W2132051411 @default.
• W2136702976 cites W2136390065 @default.
• W2136702976 cites W2138250098 @default.
• W2136702976 cites W2139677318 @default.
• W2136702976 cites W2139860898 @default.
• W2136702976 cites W2142412288 @default.
• W2136702976 cites W2146465225 @default.
• W2136702976 cites W2148445666 @default.
• W2136702976 cites W2149218924 @default.
• W2136702976 cites W2158011521 @default.
• W2136702976 cites W2158734599 @default.
• W2136702976 cites W2161817637 @default.
• W2136702976 cites W2161962336 @default.
• W2136702976 cites W2165938581 @default.
• W2136702976 cites W2167331614 @default.
• W2136702976 cites W2167368056 @default.
• W2136702976 doi "https://doi.org/10.1186/1471-2407-14-742" @default.
• W2136702976 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4190397" @default.
• W2136702976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25277255" @default.
• W2136702976 hasPublicationYear "2014" @default.
• W2136702976 type Work @default.
• W2136702976 sameAs 2136702976 @default.
• W2136702976 citedByCount "16" @default.
• W2136702976 countsByYear W21367029762015 @default.
• W2136702976 countsByYear W21367029762016 @default.
• W2136702976 countsByYear W21367029762017 @default.
• W2136702976 countsByYear W21367029762019 @default.
• W2136702976 countsByYear W21367029762021 @default.
• W2136702976 countsByYear W21367029762022 @default.
• W2136702976 countsByYear W21367029762023 @default.
• W2136702976 crossrefType "journal-article" @default.
• W2136702976 hasAuthorship W2136702976A5002433717 @default.
• W2136702976 hasAuthorship W2136702976A5011934704 @default.
• W2136702976 hasAuthorship W2136702976A5027500644 @default.
• W2136702976 hasAuthorship W2136702976A5048718607 @default.
• W2136702976 hasAuthorship W2136702976A5062856863 @default.
• W2136702976 hasAuthorship W2136702976A5070293723 @default.
• W2136702976 hasAuthorship W2136702976A5074923974 @default.
• W2136702976 hasAuthorship W2136702976A5074942308 @default.
• W2136702976 hasAuthorship W2136702976A5086027443 @default.
• W2136702976 hasBestOaLocation W21367029761 @default.
• W2136702976 hasConcept C121608353 @default.
• W2136702976 hasConcept C126322002 @default.
• W2136702976 hasConcept C142724271 @default.
• W2136702976 hasConcept C2776232967 @default.
• W2136702976 hasConcept C2776256026 @default.
• W2136702976 hasConcept C2776539811 @default.
• W2136702976 hasConcept C2777783956 @default.
• W2136702976 hasConcept C2779422266 @default.
• W2136702976 hasConcept C2779490328 @default.
• W2136702976 hasConcept C2780192828 @default.
• W2136702976 hasConcept C2781064419 @default.
• W2136702976 hasConcept C502942594 @default.
• W2136702976 hasConcept C71924100 @default.
• W2136702976 hasConceptScore W2136702976C121608353 @default.
• W2136702976 hasConceptScore W2136702976C126322002 @default.
• W2136702976 hasConceptScore W2136702976C142724271 @default.
• W2136702976 hasConceptScore W2136702976C2776232967 @default.
• W2136702976 hasConceptScore W2136702976C2776256026 @default.

• next